Microbial & Mammalian Manufacturing
Dharma Biologics | Bengaluru, India
Drug substance manufacturing is where biologics programs are truly won or lost. Decisions made at this stage determine not only yield and cost, but impurity burden, downstream complexity, formulation risk, and long-term regulatory flexibility. When drug substance processes are weak, drug product teams are forced to compensate downstream, often with fragile or expensive solutions. When drug substance processes are strong, everything that follows becomes simpler, more predictable, and more defensible.
Dharma Biologics operates as a drug substance CDMO in India with the explicit goal of building upstream processes that behave predictably under scale, scrutiny, and time. We do not chase maximum titers at the expense of control. We design drug substance processes that are manufacturable, transferable, and explainable.
As a drug substance CDMO in India, our approach is grounded in deep process understanding rather than platform dogma. Microbial and mammalian systems are treated as distinct biological and engineering problems, each requiring tailored strategies.
Drug Substance Strategy: Process Understanding Before Scale
Many drug substance failures originate from premature scale-up. Processes that appear robust at small scale collapse when oxygen transfer, heat removal, or mixing dynamics change. Dharma Biologics avoids this by anchoring development in mechanistic understanding before committing to scale.
We characterize how cells behave under stress, how metabolites accumulate, how impurities form, and how these factors interact with downstream purification. Scale-up decisions are made with full awareness of what will change physically and biologically as volumes increase. This discipline is a defining feature of a mature drug substance CDMO in India.
Mammalian Cell Culture Drug Substance
Mammalian expression systems remain essential for complex biologics requiring correct folding and post-translational modification. However, mammalian cultures are inherently sensitive to nutrient balance, metabolic byproducts, and environmental drift. Small deviations can alter glycosylation, charge variants, and impurity profiles in ways regulators notice immediately.
Dharma Biologics supports mammalian drug substance manufacturing using suspension-based platforms designed for robustness rather than fragility. We focus on maintaining consistent critical quality attributes while enabling efficient production.
Our mammalian drug substance capabilities include:
- CHO-based expression platforms optimized for productivity and quality consistency
- HEK-based systems for complex or difficult-to-express proteins
- Fed-batch and intensified culture strategies
- Defined and chemically defined media systems
- Controlled feeding profiles to manage lactate and ammonia
- Perfusion-ready process architectures where justified
Upstream processes are designed with downstream consequences in mind. Expression levels are balanced against impurity load. Culture conditions are tuned to support consistent glycosylation. This upstream–downstream alignment reduces purification complexity and improves overall process robustness.
Microbial Drug Substance Manufacturing
Microbial expression systems offer speed, scalability, and cost advantages, but they introduce distinct challenges. High cell density cultures amplify oxygen demand and heat generation. Misfolding, inclusion bodies, and endotoxin management become dominant concerns. Aggressive expression strategies often increase yield while degrading product quality.
As a drug substance CDMO in India, Dharma Biologics operates microbial platforms with restraint and control. We engineer processes that remain manageable at scale rather than pushing cells beyond their biological limits.
Our microbial drug substance capabilities include:
- E. coli expression systems for enzymes and recombinant proteins
- Yeast expression platforms for secreted or complex proteins
- High-cell-density fed-batch fermentation
- Defined and semi-defined media strategies
- Advanced oxygen transfer and heat removal solutions
- Integrated endotoxin control strategies
Microbial processes are developed to balance expression rate with folding capacity and downstream purification requirements. This reduces aggregation, simplifies purification, and improves batch consistency.
Cell Line and Strain Engineering
The quality of a drug substance process is heavily influenced by the starting biology. Poorly characterized cell lines or strains propagate variability throughout manufacturing. Dharma Biologics invests heavily in cell line and strain understanding to ensure long-term stability.
We evaluate genetic stability, productivity drift, and stress response under manufacturing conditions. Selection criteria extend beyond initial titer to include robustness, impurity profile, and scalability. This focus is essential for any drug substance CDMO in India supporting late-stage or commercial programs.
Process Development and Optimization
Process development at Dharma Biologics is structured to generate understanding, not just data. We study how changes in pH, temperature, feeding strategy, and aeration influence cell behavior and product quality. Development work is explicitly designed to inform scale-up and validation rather than producing isolated optimization results.
Optimization is approached conservatively. We prioritize wide operating windows and reproducibility over narrow optima that cannot be maintained in manufacturing. This philosophy reduces risk during tech transfer and commercial operation.
Scale-Up and Tech Transfer
Scale-up is not a linear exercise. Physical forces change with scale, and biological systems respond in non-intuitive ways. Dharma Biologics approaches scale-up as a controlled translation of process intent rather than a simple increase in volume.
We model changes in mixing, mass transfer, and heat removal explicitly. Process parameters are adjusted to preserve cellular environment rather than replicate absolute values. Documentation is structured to capture rationale clearly, supporting both internal execution and regulatory review.
As a drug substance CDMO in India, we place particular emphasis on tech transfer clarity. Processes are documented in a way that enables reproducibility across equipment, sites, and time, including within the broader CDMO Network.
Downstream Integration
Drug substance manufacturing does not end at harvest. Downstream purification defines final product quality and impurity profile. Dharma Biologics integrates upstream and downstream development to ensure that purification strategies align with expression behavior.
We design downstream processes that tolerate realistic variability rather than relying on idealized inputs. This reduces batch failures and supports consistent commercial supply.
Downstream capabilities include:
- Multi-step chromatography strategies
- Affinity, ion exchange, and mixed-mode purification
- Ultrafiltration and diafiltration systems
- Viral clearance strategies aligned with global expectations
- Impurity trend monitoring across campaigns
cGMP Drug Substance Manufacturing
Commercial drug substance manufacturing requires more than scale; it requires discipline. Equipment qualification, cleaning validation, campaign planning, and data integrity must all align to support consistent execution.
Dharma Biologics operates cGMP drug substance manufacturing systems designed for inspection readiness and lifecycle durability. Processes are validated conservatively, deviations are investigated mechanistically, and data integrity is treated as operational infrastructure.
This approach allows us to support clinical through commercial programs confidently as a drug substance CDMO in India.
Regulatory Expectations and Inspection Readiness
Regulators expect deep understanding of drug substance processes, particularly for biologics. They scrutinize control strategies, impurity management, and change history closely.
Dharma Biologics embeds regulatory thinking into process design rather than retrofitting it later. We generate data that explains behavior, supports comparability, and withstands inspection. This reduces regulatory friction and supports global submissions.
Commercialization and Lifecycle Management
Drug substance processes must evolve over time. Capacity expansion, supplier changes, and process improvements are inevitable. Dharma Biologics designs processes with this reality in mind, enabling change without destabilizing quality.
Through the CDMO Network, we support redundancy and scale while maintaining standardized quality systems. Sponsors gain resilience without fragmentation.
Closing Perspective
Strong drug substance processes simplify everything that follows. Weak ones create cascading risk. Dharma Biologics operates as a drug substance CDMO in India precisely because we respect this reality.
From Bengaluru, and across our integrated network, we deliver drug substance manufacturing systems that are robust, explainable, and built for the long term.
ಮೂಲದಲ್ಲಿ ನಿಯಂತ್ರಣ. ಪ್ರಮಾಣದಲ್ಲಿ ವಿಶ್ವಾಸ.